News
Cancellation of 6,899,011 ordinary shares held in treasury by EQTThe cancellation was resolved by the Annual Shareholders' Meeting 2025As of 30 May 2025, there are 1,177,185,346 shares outstanding ...
CALGARY, AB / ACCESS Newswire / May 29, 2025 / NXT Energy Solutions Inc. ("NXT" or the "Company") (TSX:SFD)(OTCQB:NSFDF) is pleased to announce that Ataraxia Capital ("Ataraxia"), has converted all it ...
TURKU, FI / ACCESS Newswire / May 30, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Phase I study shows promising clinical activity and tolerability of bexmarilimab plus standard-of-care in hig ...
Magnum Goldcorp Inc. (TSXV: MGI) (the "Company" or "Magnum") announces that further to its news release of May 22, 2025, the Company ...
NORTHAMPTON, MA / ACCESS Newswire / May 30, 2025 / Key PointsMarathon Petroleum Corporation set a company record for recognition at this year's American Fuel & Petrochemical Manufacturers safety ...
Nova Minerals Limited ("Nova" or the "Company") (NASDAQ: NVA) (ASX: NVA) (FRA: QM3)) is pleased to announce that preparations ...
Valvoline Global is set to make its partnership debut with FIFA's flagship tournament.The sponsorship reflects the rapid ...
BURLESON, TX / ACCESS Newswire / May 29, 2025 / Sadot Group Inc. (Nasdaq:SDOT) ("Sadot Group", "Sadot" or the "Company"), today announced the appointment of Mr. Chagay Ravid as its new Chief Executive ...
MUMBAI, India and PRINCETON, N.J., May 30, 2025 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: ...
Copenhagen, 30 May 2025 Impero A/S announces today that Morten Lehmann Nielsen, the company's Chief Financial Officer and member of the Executive Board, has decided to step ...
Gross Revenue of US$19.85 Million and Cash Cost of US$874/OzVANCOUVER, British Columbia, May 30, 2025for full financial results). President and CEO Cathy Zhai commented, "In Q3 FY 2025, the flotation ...
PALO ALTO, CA / ACCESS Newswire / May 30, 2025 / Riboscience, LLC, today announced the presentation of data from the completed dose escalation Phase 1a of the Phase 1a/b clinical trial of the ENPP1 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results